CIRculating CANcer MAster-Protocol

Launched by HOSPICES CIVILS DE LYON · Oct 21, 2021

Keywords

ClinConnect Summary

The CIRculating CANcer MAster-Protocol trial is a research study aimed at understanding blood markers that may help in diagnosing cancer, assessing how well treatments are working, and tracking disease progression. This study is currently recruiting participants aged 18 and older who have been diagnosed with any type of solid cancer, as confirmed by specific medical tests. To take part, individuals must be willing to provide a blood sample as part of their regular care and must sign a consent form to join the study.

If you or a family member are considering participation, it’s important to know that you will need to meet certain criteria, such as having a solid cancer diagnosis and being able to provide a blood sample. Participants can expect to contribute to important research that may lead to improved cancer care in the future. However, those who have recently had a blood transfusion, have low hemoglobin levels, or refuse to participate will not be eligible. This trial represents an exciting opportunity to help advance our understanding of cancer through blood analysis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult (\>18y)
• • Owing a social security insurance
• • Any solid cancer diagnosed by histopathology or cytology
• • Patient with blood sampling required as per standard of care
• • Informed consent signed
• Exclusion Criteria:
• • Refusal to participate
• • No blood sampling required as per standard of care
• • Hemoglobin \< 7g/dl (\< 9g/dl if respiratory or cardiovascular disease history)
• • Heterologous blood transfusion in the last 48 hours
• • Weight under 20 kg